Alerje

03/23/2026

https://www.inc.com/elisa-miller-out/founder-javier-evelyn-alerje-sempresto-food-allergies-lifesaving-startup-chloe-capital/91317659

Alerje founder Javier Evelyn's mobile auto-injector platform was recently acquired by SemPresto.

12/04/2025

Today marks an important milestone in our patient led journey at Alerje. After years of building award winning technology and securing 13 patents, we have officially transitioned our epinephrine device asset to SemPresto, Inc 🎉! This honors the legacy of a product that began as a deeply personal solution and places it with a world class team that has driven more than half a billion dollars in fundraising and exits.

Alerje continues on. This transition reflects the direction we have been moving for the past few years as we shifted our focus toward the FAIT platform and the future of collaborative, connected food allergy care. Our mission to improve outcomes for families remains as strong as ever. What is evolving is how we deliver that mission, and this next chapter positions us to move faster and with greater impact through software and real world implementation.
We are grateful for our team, investors, partners, and for recognitions from CES, the National Science Foundation, state leadership, and others who have supported this work. We are energized for what 2026 holds!

Press Release: https://www.businesswire.com/news/home/20251204523180/en/Sempresto-Acquires-Alerjes-Autoinjector-Platform-to-Accelerate-Commercialization-of-Smartphone-Integrated-Rescue-Medications